Key Points
- Director purchase: Entrada Therapeutics director Bernhardt Zeiher bought 5,000 shares at $5.86 each, a $29,300 transaction disclosed in an SEC filing.
- Stock movement and valuation: The stock rose 4.5% and opened at $6.31, giving the company a market cap of about $245 million. It remains well below its 52-week high of $16.45.
- Analyst and earnings backdrop: Entrada recently beat EPS expectations but missed revenue estimates, and Wall Street currently rates the stock a Moderate Buy with an average price target of $18.25.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Bernhardt Zeiher acquired 5,000 shares of the stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $5.86 per share, with a total value of $29,300.00. Following the completion of the purchase, the director owned 5,000 shares of the company's stock, valued at approximately $29,300. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Entrada Therapeutics Trading Up 4.5%
Entrada Therapeutics stock opened at $6.31 on Friday. The firm has a market cap of $244.96 million, a P/E ratio of -1.58 and a beta of -0.09. Entrada Therapeutics, Inc. has a 1-year low of $4.93 and a 1-year high of $16.45. The firm has a 50-day moving average of $11.67 and a 200-day moving average of $10.88.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.06) by $0.11. The company had revenue of $0.88 million for the quarter, compared to the consensus estimate of $2.92 million. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%. Research analysts forecast that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Entrada Therapeutics
A number of institutional investors have recently added to or reduced their stakes in TRDA. Millennium Management LLC lifted its position in Entrada Therapeutics by 391.2% during the third quarter. Millennium Management LLC now owns 836,609 shares of the company's stock valued at $4,852,000 after buying an additional 666,287 shares during the period. Citadel Advisors LLC grew its position in shares of Entrada Therapeutics by 234.5% in the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company's stock worth $1,947,000 after buying an additional 235,384 shares during the period. Baker BROS. Advisors LP grew its position in shares of Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company's stock worth $52,148,000 after buying an additional 206,911 shares during the period. Qube Research & Technologies Ltd increased its stake in shares of Entrada Therapeutics by 115.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company's stock worth $1,670,000 after acquiring an additional 154,143 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Entrada Therapeutics by 4,767.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 148,212 shares of the company's stock worth $860,000 after acquiring an additional 145,167 shares in the last quarter. Institutional investors own 86.39% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on TRDA shares. Cantor Fitzgerald started coverage on Entrada Therapeutics in a report on Wednesday, April 1st. They set an "overweight" rating for the company. Oppenheimer lifted their price target on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the company an "outperform" rating in a report on Monday, April 6th. Guggenheim raised shares of Entrada Therapeutics to a "strong-buy" rating in a research report on Wednesday, February 11th. HC Wainwright lowered shares of Entrada Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, May 8th. Finally, Roth Mkm set a $10.00 target price on shares of Entrada Therapeutics in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Entrada Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $18.25.
View Our Latest Research Report on Entrada Therapeutics
Entrada Therapeutics Company Profile
(
Get Free Report)
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
